News

Press Releases

Press Releases

Press Releases

September 2, 2020
Osmotica to Present at 2020 Wells Fargo Virtual Healthcare Conference
BRIDGEWATER, N.J. , Sept. 02, 2020 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, announced today that Brian Markison , Chief Executive Officer, and James “JD” Schaub, Chief Operating Officer, will present
July 28, 2020
Santen and RVL Pharmaceuticals, Inc., an Osmotica Company, Enter into an Exclusive License Agreement in Japan, Asia, and EMEA for RVL-1201, a First-in-Class Treatment for Acquired Blepharoptosis
OSAKA, Japan and BRIDGEWATER, N.J. , July 28, 2020 (GLOBE NEWSWIRE) -- Santen Pharmaceutical Co., Ltd (hereinafter, Santen) and RVL Pharmaceuticals, Inc. , a subsidiary of Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (hereinafter, Osmotica), announced today an exclusive license agreement covering
July 13, 2020
Osmotica Announces Pricing of Public Offering of Ordinary Shares
BRIDGEWATER, N.J. , July 13, 2020 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, announced today the pricing of its previously announced public offering of 5,000,000 ordinary shares at a price to the
July 13, 2020
Osmotica Announces Proposed Public Offering of Ordinary Shares
BRIDGEWATER, N.J. , July 13, 2020 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, announced today the commencement of a proposed public offering of 5,000,000 ordinary shares.
Displaying 1 - 10 of 21